Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Latest News on JSPR

Mar 1, 2025, 12:45 PM EST - 7 weeks ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 7 weeks ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 7 weeks ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 7 weeks ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 2 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 2 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 3 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 3 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 4 months ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 5 months ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 5 months ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 5 months ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 6 months ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 6 months ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 6 months ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 7 months ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 8 months ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 8 months ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 10 months ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jun 17, 2024, 4:30 PM EDT - 10 months ago

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 14, 2024, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

May 30, 2024, 6:05 PM EDT - 11 months ago

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024, 4:30 PM EDT - 11 months ago

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 7, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Apr 2, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Mar 15, 2024, 8:00 AM EDT - 1 year ago

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Mar 4, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Feb 26, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Feb 23, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 7, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Feb 6, 2024, 8:59 AM EST - 1 year ago

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Feb 5, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2024, 8:30 AM EST - 1 year ago

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Jan 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Announces Reverse Stock Split

Dec 10, 2023, 11:00 AM EST - 1 year ago

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

Nov 30, 2023, 8:00 AM EST - 1 year ago

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Nov 9, 2023, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Oct 9, 2023, 8:30 AM EDT - 1 year ago

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Oct 9, 2023, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

Sep 25, 2023, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium

Sep 15, 2023, 8:00 AM EDT - 1 year ago

Market Cap	59.64M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	85,800
Avg Vol	278,290
Day's Range	N/A - N/A
Shares Out	15.02M
Stochastic %K	66%
Beta	2.55
Analysts	Strong Sell
Price Target	$58.50